Trials / Completed
CompletedNCT03811652
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 101 Years
- Healthy volunteers
- Not accepted
Summary
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or metastatic solid tumor malignancies that have received at least 1 prior line of treatment.
Conditions
- Non Small Cell Lung Cancer Squamous (NSCLC-Sq)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Small Cell Lung Cancer (SCLC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Colorectal Cancer (CRC)
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI7247 | Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule |
Timeline
- Start date
- 2018-12-20
- Primary completion
- 2019-12-10
- Completion
- 2019-12-10
- First posted
- 2019-01-22
- Last updated
- 2019-12-30
Locations
3 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03811652. Inclusion in this directory is not an endorsement.